Background Cannabis use rates are increasing among adults in the United States (US) while the perception of harm is declining. This may result in an increased prevalence of cannabis use disorder and the need for more clinical trials to evaluate efficacious treatment strategies. Clinical trials are the gold standard for evaluating treatment, yet study samples are rarely representative of the target population. This finding has not yet been established for cannabis treatment trials. This study compared demographic and cannabis use characteristics of a cannabis cessation clinical trial sample (run through National Drug Abuse Treatment Clinical Trials Network) with three nationally representative datasets from the US; 1) National Survey on Drug Use and Health, 2) National Epidemiologic Survey on Alcohol and Related Conditions-III, and 3) Treatment: Episodes Data Set – Admissions. Methods Comparisons were made between the clinical trial sample and appropriate cannabis using sub-samples from the national datasets, and propensity scores were calculated to determine the degree of similarity between samples. Results showed that the clinical trial sample was significantly different from all three national datasets, with the clinical trial sample having greater representation among older adults, African Americans, Hispanic/Latinos, adults with more education, non-tobacco users, and daily and almost daily cannabis users. Conclusions These results are consistent with previous studies of other substance use disorder populations and extend sample representation issues to a cannabis use disorder population. This illustrates the need to ensure representative samples within cannabis treatment clinical trials to improve the generalizability of promising findings.
|Number of pages||7|
|Journal||Drug and Alcohol Dependence|
|State||Published - Jul 1 2017|
Bibliographical noteFunding Information:
This study was supported by grants from the National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (U10DA013727) and NIDA Contracts N01DA92217 and N01DA102221 (The EMMES Corporation). Effort to support the writing of this manuscript was provided by NIDA grants K01 DA036739 (EAM). UEG has not had and will not have any programmatic responsibility for the K01 grant to EAM and any of the other non-cooperative agreement grants cited. The funding agencies had no further role in study design, analysis, interpretation, or in writing the report.
© 2017 Elsevier B.V.
- Cannabis use disorder
- Clinical trial
- Sample representativeness
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)